Sentence examples for cumulative safety data from inspiring English sources

The DSMB and the local safety monitor reviewed the cumulative safety data and provided the investigators, through the sponsor, with a written authorization to proceed to the next vaccination and dose escalation at each stage.

We are also presenting the cumulative safety data for the entire study up to the last dose administered (week 104).

The 20.0 mg/kg single-dose group and all multiple-dose groups were enrolled simultaneously, after the cumulative safety data for the lower single doses were approved.

Cumulative safety data for 12 months were collected and analysed from the combined period of the maintenance of effect phase of the core study and the extension study.

Cumulative safety data (as of February 6 , 2009 from five core phase 3 trials, two ongoing extension trials, and one clinical pharmacology study were analyzed.

The cumulative safety data across many trials show that agents that inhibit CTLA-4 are generally safe, with unique, but usually manageable, side effects that are linked to their mechanism of stimulating immune responses.

Escalation to the next dose level proceeded only after the Safety Review Team reviewed cumulative, blinded safety data when at least six subjects completed Day 29 in the previous cohort.

The aim of this study is to gather safety data on cumulative sessions of tDCS in acute subacute phases of stroke, obtain information about effects of this intervention on important physiologic and clinically relevant swallowing parameters, and examine possible dose effects.

A summary of the clinical efficacy data from each of the main phase II and III trials of abatacept in RA is first presented, followed by cumulative quality of life and safety data.

In our previous article, we reported the results of analyses of dose intensity, treatment duration, and cumulative oxaliplatin dose in the six studies and concluded that the comparison of safety data among these studies was feasible and informative [ 29].

Preliminary safety data of the phase III trial evaluating BEV plus FOLFOXIRI versus BEV plus FOLFIRI, show cumulative G3-4 toxicities prevalently represented by diarrhea (18%), stomatitis/mucositis (8%), asthenia (4%), hypertension (2%), trombotic events (8%), neutropenia (53%), febrile neutropenia (6%); a treatment-related death was reported in 1 patient (gastrointestinal bleeding; 2%).